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Noncommunicable diseases (NCDs) are the most common
causes of premature death and morbidity and have a major
impact on health-care costs, productivity, and growth.
Cardiovascular disease, cancer, diabetes, and chronic
respiratory disease have been prioritized in the Global NCD
Action Plan endorsed by the World Health Assembly, because
they share behavioral risk factors amenable to public-health
action and represent a major portion of the global NCD
burden. Chronic kidney disease (CKD) is a key determinant of
the poor health outcomes of major NCDs. CKD is associated
with an eight- to tenfold increase in cardiovascular mortality
and is a risk multiplier in patients with diabetes and
hypertension. Milder CKD (often due to diabetes and
hypertension) affects 5–7% of the world population and is
more common in developing countries and disadvantaged
and minority populations. Early detection and treatment of
CKD using readily available, inexpensive therapies can slow
or prevent progression to end-stage renal disease (ESRD).
Interventions targeting CKD, particularly to reduce urine
protein excretion, are efficacious, cost-effective methods of
improving cardiovascular and renal outcomes, especially
when applied to high-risk groups. Integration of these
approaches within NCD programs could minimize the need
for renal replacement therapy. Early detection and treatment
of CKD can be implemented at minimal cost and will reduce
the burden of ESRD, improve outcomes of diabetes and
cardiovascular disease (including hypertension), and
substantially reduce morbidity and mortality from NCDs.
Prevention of CKD should be considered in planning and
implementation of national NCD policy in the developed and
developing world.
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Noncommunicable diseases (NCDs) have replaced commu-
nicable diseases as the most common causes of morbidity and
premature mortality worldwide.1–3 An estimated 80% of the
burden occurs in low- or middle-income countries, and 25%
is in people younger than 60 years.1 Moreover, the global
economic impact of NCDs is enormous: by 2015, just two
diseases (cardiovascular disease and diabetes) are expected to
reduce global gross domestic product by 5%.1 Approximately
half of the total economic burden is accounted for by
cardiovascular disease including stroke, ischemic heart
disease, and peripheral vascular disease, which together cause
more deaths than HIV/AIDS, malaria, and tuberculosis
combined.1,4 In recognition of the increasing burden and
importance of chronic diseases, in 2008 the World Health
Assembly endorsed a Global NCD Action Plan for NCD
prevention and control.5
Four NCDs (cardiovascular disease, cancer, diabetes, and
chronic respiratory disease) have been prioritized in the
Global NCD Action Plan endorsed by the World Health
Assembly in 2008 because they share major behavioral risk
factors amenable to public-health action and together
contribute to a major portion of the global NCD burden.
Although not currently identified as a separate target, there is
compelling evidence that kidney disease is a key determinant
of the poor health outcomes of diabetes and cardiovascular
disease (including hypertension), and prevention of kidney
disease requires attention within national NCD programs
particularly at the primary-care level as recommended by
the WHO.2,6
CHRONIC KIDNEY DISEASE: THE GLOBAL PERSPECTIVE
Importance of chronic kidney disease
One potential outcome of chronic kidney disease (CKD) is
end-stage renal disease (ESRD), requiring costly renal
replacement therapy in the form of dialysis or transplanta-
tion. In developed countries, ESRD is a major cost driver for
health-care systems, with annual growth of dialysis programs
ranging between 6% and 12% over the past two decades and
continuing to grow, particularly in developing countries.
Although the incidence of ESRD shows signs of leveling off in
developed countries, perhaps in part because of increased
awareness of CKD, no such trend is seen in developing
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countries or minority populations. Over 2 million people
now require renal replacement therapy to sustain life
worldwide, but this likely represents less than 10% of those
who need it.6 In middle-income countries, access to these
life-saving therapies has progressively increased over the
same period. Efforts continue to reduce the cost of chronic
dialysis, and to make kidney transplantation more widely
available as the cost of immunosuppressive medications
comes down; but nevertheless renal replacement therapy
remains unaffordable for the majority of the affected and
causes severe financial hardship for those who have access
to it.2 Another 112 countries, with a combined population
of over 600 million people, cannot afford renal replacement
at all—resulting in the death of over 1 million people
annually from untreated kidney failure.3,7 Motivated by the
dismal outcomes and high costs associated with kidney
failure, the past two decades have witnessed a marked
increase in attention to the prevalence, prevention, and
consequences of earlier and milder forms of renal impair-
ment (CKD).
i. CKD is increasingly common in developed and developing
nations. Kidney disease is conventionally assessed in terms
of both overall renal function (glomerular filtration rate,
GFR) and the presence of kidney damage ascertained by
either kidney biopsy or other markers of kidney damage
such as proteinuria (also termed albuminuria and defined
by a urine albumin/creatinine ratio of 430 mg/g or urine
protein/creatinine ratio 4200 mg/g), abnormal urinary
sediment, abnormalities on imaging studies, or the presence
of a kidney transplant.8 GFR is estimated in clinical practice
using readily calculated equations that adjust serum creati-
nine values to age, sex, and ethnicity. It is important to
recognize that both serum creatinine and albuminuria can be
easily assessed using readily available, inexpensive laboratory
testing.6
CKD is classified into stages 1–5, with stages 1 and 2
requiring the presence of kidney damage such as proteinuria
as well as reduced GFR.8 Many authors now refer to
‘moderate,’ or clinically significant, CKD as stages 3
(GFR 30–59 ml/min) and 4 (GFR 15–29 ml/min), with
o60 ml/min chosen as a cutoff because it represents loss of
about 50% of normal renal function, although there is now
ample evidence of increased risk in earlier stages.9,10 The role
of proteinuria as well as GFR measurements in assessing risk
of CKD is particularly important since people with stage 1–2
CKD and proteinuria have worse outcomes than people with
stage 3 and no proteinuria, and development of both ESRD
and cardiovascular disease is predicted much more accurately
by proteinuria measurements than by GFR.9,10 A recent
meta-analysis of eight cohorts of 845,125 general and high-
risk people confirms the marked and graded increased risk
for ESRD in those with a GFR less than 60 ml/min (stage 3)
and in people with albuminuria at all levels independent
of traditional cardiovascular risk factors.11 Stage 5 CKD is
ESRD and is identified by GFR less than 15 ml/min or the
need for dialysis.
This classification system has generated controversy
regarding whether people identified as having CKD based
primarily on estimated GFR measurements, particularly the
elderly, actually have a ‘disease.’12 It has also required some
modifications for different ethnic groups.13,14 Newer schemes
have been proposed to overcome many of the concerns about
the Kidney Disease Outcomes Quality Initiative (KDOQI)
classification.15,16 Using a modification of the original GFR
estimating equation (CKD-EPI equation), 11.6% of adult
US residents have CKD stages 1–4 (approximately 26 million
people), and the prevalence has increased over the past
decade.15 Of these, about 65% (7.5% of the total population)
had moderate CKD (stage 3 or 4).16 Similar figures have been
reported from several other countries.2,3,17,18
According to the 2010 US Renal Data System Annual Data
Report, the leading causes of CKD leading to kidney failure
in the United States are diabetes (incident cases of ESRD of
153 per million population in 2009), hypertension (account-
ing for 99 per million population), and glomerulonephritis,
which accounts for 23.7 per million population;19 cardio-
vascular disease is also an important cause. However, in the
United States about 28% of patients with clinically significant
(stage 3 or worse) CKD are neither diabetic nor hypertensive,
particularly those older than 65 years.19,20 The proportion of
people with CKD not explained by diabetes or hypertension
is substantially higher in developing countries. In developing
countries, diabetes and hypertension now appear to be the
leading causes of ESRD with a prevalence of about 30%
and 21%, respectively, but glomerulonephritis and CKD of
unknown origin account for a larger fraction of the total,
especially in younger patients. For example, in a recent study
of people with CKD detected by International Society
of Nephrology-sponsored screening programs in China,
Mongolia, and Nepal, 43% of people with CKD did not
have diabetes or hypertension.21 The estimated prevalence of
moderate CKD in developed countries is variable but is
generally between 5% and 7% of the total adult population
and consistently increases over time within countries.2,3,7
Given projected increases in the prevalence of major risk
factors for CKD (including diabetes, hypertension, and
cardiovascular disease), the prevalence of CKD in developing
countries is expected to dramatically increase over the next
two decades. Other less recognized factors will contribute as
well. For example, there is strong evidence that intrauterine
events linked to poor nutrition alter prenatal programming
and lead to low nephron number, which represents another
substantial risk factor for CKD in later life.22 This is relevant
to global health given the emerging food crises worldwide.
Over 2 million people are being kept alive by renal
replacement therapy worldwide, the majority of whom are
treated in only five countries (US, Japan, Germany, Brazil,
and Italy) that constitute only 12% of world population.
Only 20% are treated in about 100 developing countries that
make up over 50% of world population. This depicts a clear
and direct association between gross domestic product and
availability of renal replacement therapy.
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ii. CKD is harmful and expensive. Although more than 2
million people already have ESRD, it is now established that
(even in developed nations) only a small minority of people
with CKD will develop kidney failure, partly because of
the competing risk of cardiovascular mortality. For instance,
data from the United States show that for every patient
with ESRD, there are more than 200 with overt CKD (stage
3 or 4) and almost 5000 with covert disease (stage 1 or 2).23
In stage 3, representing almost 40% of the CKD population,
the number that will progress to ESRD is estimated at only
about 0.15–0.2% per year over 10–25 years.24–26 A much
greater problem is the now well-documented eight- to ten-
fold increase in cardiovascular disease mortality in CKD
populations, thus strongly linking CKD to cardiovascular
disease, one of the four major NCDs prioritized in the Global
NCD Action Plan (see below).24,25,27
The most obvious societal effect of CKD is the enormous
financial cost and loss of productivity associated with
advanced kidney disease. For instance, many developed
nations spend more than 2–3% of their annual health-care
budget to provide treatment for ESRD, while the population
with ESRD represents approximately 0.02–0.03% of the total
population.28 The economic burden associated with milder
forms of CKD is huge: more than twice the total cost of
ESRD. In the United States, monthly costs associated with
managing CKD alone are $1250 per month, and more than
$3000 per month if diabetes and heart failure are present.19
Medicare expenditures on CKD patients in the United States
exceeded $60 billion in 2007 versus $25 billion for ESRD and
represented 27% of the total Medicare budget.19 These figures
illustrate the ‘multiplier effect’ of CKD on morbidity and
mortality as well as cost.
Moreover, CKD is associated with extremely high morbid-
ity and mortality even in its earlier stages.29–33 In the extreme,
mortality of ESRD patients is 10 to 100 times greater than in
age-matched controls with normal kidney function. ESRD is
associated with very low quality of life—an average patient
would be willing to give up 10 years of life on dialysis
in exchange for 4 years with normal kidney function. The
high burden of ESRD and associated costs, related adverse
outcomes, and decreased productivity make it a significant
public-health problem worldwide. Similar associations be-
tween CKD, ESRD, and events predictive of later cardiovas-
cular disease have also been well documented in children.34–36
This situation is even worse in most developing nations,
where ESRD constitutes a ‘death sentence,’ as renal replace-
ment therapy is often unavailable or unaffordable: nearly
1 million people die with ESRD each year in developing
nations.7 At the individual level, CKD affects all facets of
health: physical (increased burden of cardiovascular disease
morbidity and mortality) and social (low quality of life,
decreased productivity and job losses, family pressures, and
mental disorders).37,38
iii. CKD is treatable. In the past decades, ample evidence
from clinical trials and meta-analyses has shown the efficacy
of several management options for CKD to reduce risk of
progression to ESRD and to lower cardiovascular risk.39,40
These treatments are based on the control of its established
modifiable risk factors. Control of hypertension is the single
most effective intervention. Pooled analyses of many of these
studies have consistently shown that the lower the blood
pressure, the slower the progression of CKD.41 Control of
proteinuria with inhibitors of the renin–angiotensin system is
highly effective for slowing the progression of diabetic and
nondiabetic CKD. In, addition, lifestyle intervention (weight
loss, smoking cessation), tight diabetes control, and treat-
ment of other cardiovascular risk factors such as dyslipi-
demia are linked to lower rates of progression to ESRD, and
associated with significant reduction in cardiovascular
morbidity and mortality. These interventions are integrated
with the WHO core package of essential NCD interventions
for primary care.6
iv. CKD disproportionately affects the poor. In addition to
the well-documented relationships linking poverty with
hypertension, diabetes, and cardiovascular disease, low
socioeconomic status is also associated with CKD. In the
National Health and Nutrition Examination Surveys
(NHANES), people with lower income were disproportio-
nately afflicted with a higher burden of CKD risk factors.42
Lower income and social deprivation are associated with
microalbuminuria, macroalbuminuria, reduced GFR, pro-
gressive kidney function loss, ESRD, and (among those with
ESRD) less access to renal transplantation in studies from
multiple developed nations.42–54 Within the developing
world, similar associations between lower income and
increased burden of CKD are also seen. More importantly,
the overall burden of CKD is already greater in developing
nations than in developed nations—and due to the epidemic
of diabetes, hypertension, and cardiovascular disease in these
low-income settings, further rapid growth will continue.7,55
Sadly, CKD already disproportionately affects the poor and
the socially disadvantaged—a situation that is also expected
to worsen over the coming decades.7,18
v. Awareness of CKD is low. As with many NCDs,
awareness of CKD is low, generally less than 20%, even at
more advanced stages and in developed nations.20 In the
United States, fewer than 5% of people with an estimated
GFR less than 60 ml/min per 1.73 m2 and proteinuria as a
marker of kidney damage were aware of having CKD.20 In
those with CKD stage 3, awareness was only 7.5%, and for
stage 4, less than 50%.20 Awareness rates among those with
CKD stage 3 or 4 were higher if comorbid diagnoses of
diabetes and hypertension were present, but even then they
were quite low (20% and 12%, respectively). As an example,
in a recent analysis of almost 500,000 people in Taiwan who
took part in a standard medical screening program, 12% had
CKD, and less than 4% of those with CKD were aware of
their condition.27 Awareness of CKD in developing nations is
markedly lower, which probably serves as a barrier to
accessing appropriate care even where available.56
vi. The presence of CKD dramatically increases the risk of
adverse outcomes among people with other NCDs. The majority
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of patients with CKD have diabetes, hypertension, and/or
cardiovascular disease19—driven by a reciprocal relationship
among these four major chronic diseases. CKD strongly
predisposes to hypertension and cardiovascular disease;
diabetes, hypertension, and cardiovascular disease are all
major causes of CKD; major risk factors for diabetes,
hypertension, and cardiovascular disease (such as obesity
and smoking) also cause or exacerbate CKD; and evidence-
based treatments for slowing progression of CKD also reduce
complications from diabetes, hypertension, and cardiovas-
cular disease. Just as costs are highest among people with
CKD superimposed on other chronic diseases, the presence of
CKD (reduced estimated GFR or proteinuria) identifies the
subset of people with diabetes, hypertension, or cardiovas-
cular disease who are at the highest risk of adverse outcomes
but are least likely to receive appropriate treatment. There-
fore, where resources are limited, the presence of CKD
could be used to identify people with diabetes, hypertension,
and/or cardiovascular disease in whom intervention might be
most beneficial and economically attractive.1,6
vii. CKD is also linked to acute kidney injury. CKD not only
increases risk of both ESRD and cardiovascular disease but is
also associated with a significant and often preventable
increase in risk of acute (reversible) kidney injury (AKI),
which markedly worsens outcomes.57 Although studied
mostly in hospitalized patients and in developed countries,
the incidence of AKI is estimated at about 5–7% of all
hospitalized patients, with the highest incidence in those with
cardiovascular disease.58 AKI with an increase in serum
creatinine of p167 mmol/l (2.0 mg/dl) is associated with a
tenfold increase in mortality and threefold increase in cost
of hospitalization—and 40-fold and sixfold increases in
mortality and costs, respectively, if the rise is greater than
167 mmol/l.58 In the United States alone the costs of AKI have
been estimated at about $10 billion per year, or 40% of the
costs of treating patients with ESRD.58
Even transient increases in serum creatinine of as little as
25 mmol/l in patients with CKD increase both the rate of
progression to ESRD and all-cause mortality in comparison
with patients without CKD.59
Such transient episodes of AKI can occur with several
cardiovascular and diabetes medications, nonsteroidal anti-
inflammatory agents, and traditional medicines used in
developing-country primary-care settings, emphasizing the
importance of CKD detection and appropriate adjustments
in management for optimal outcomes in major NCDs. With
respect to CKD, increased risk of AKI ranges from 3.54-fold
in patients with stage 3 CKD and proteinuria to 28.5-fold in
patients with stage 4, and up to 28% of patients with no
preexisting kidney disease who recover from AKI develop
de novo CKD.60 Not only is acute dialysis for AKI extremely
expensive and associated with poor outcomes, but it is
not available in many developing-country settings, resulting
in death from treatable and reversible causes for many
young people with AKI due to things like dehydration or
complications of pregnancy.
viii. Summary. CKD is a significant public-health
problem,61 on the basis of the tremendous burden of death
and disability that it causes, its inequitable distribution
among the poor, and the existence of effective and affordable
treatments that are not available to a large proportion of
those affected. In the sections below we summarize the data,
which support the linkage of CKD to diabetes, hypertension,
and cardiovascular disease and thereby the rationale for
considering prevention of CKD through early detection and
treatment in national NCD policy agendas particularly at the
primary-care level.6
CKD and diabetes
i. Diabetes is a major public-health problem. Over the past
25 years, the prevalence of type 2 diabetes has almost
doubled in the United States and has increased three- to
fivefold in India, Indonesia, China, Korea, and Thailand.62,63
As with other NCDs, the increase in prevalence of diabetes
will be most rapid in developing countries. According to
the WHO, China and India will have about 130 million
people with diabetes in 2025, and these people will consume
about 40% of total health expenditures in the countries.1
Indeed, 30% of the predicted $1.1 trillion global cost
of dialysis during the current decade will result from diabetic
nephropathy, now the most common cause of ESRD
worldwide.62,63 Despite this, only 8.7% of the general
population was able to identify diabetes as a risk factor for
kidney disease,64 and among patients with diabetic kidney
disease, very few are aware of their kidney condition.62,65
The increasing prevalence of diabetes has been called, with
some justification, ‘a medical catastrophe of worldwide
dimensions.’65
ii. Diabetes is a major cause of CKD. CKD is common in
diabetes and is a major determinant of adverse outcomes.
Over 5% of people with newly diagnosed type 2 diabetes
already have CKD, and an estimated 40% of both type 1 and
type 2 diabetics will develop CKD during their lifetimes—the
majority within 10 years of diagnosis.66,67 The prevalence of
stage 3 or worse CKD in US diabetics exceeds 15%,19,20 and
CKD in diabetes carries an increased risk of progression to
ESRD,63 a death sentence in many parts of the world where
dialysis is not available or affordable. About 45% of patients
with ESRD in most developed countries have diabetes.62,63
Reduced GFR and albuminuria caused by diabetic nephrop-
athy are each major independent risk factors for both
cardiovascular events and death.68,69 In patients with ESRD
due to diabetes, the prevalence of ischemic heart disease is
increased 78%, and of congestive heart failure by 100%, over
those in nondiabetic controls.70 Although diabetic CKD is
common, it is often unrecognized and untreated, especially in
people with other NCDs: among people with diabetes and
normal serum creatinine levels who undergo coronary
interventions, 77% have CKD.71
iii. If recognized early, diabetic CKD can be effectively
treated. However, the good news is that relatively simple
and inexpensive approaches are now available to address
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diabetes and diabetic nephropathy. Such programs include
opportunistic screening in primary health care settings,
lifestyle changes, and cost-effective medical interventions that
are now both doable and affordable.6,72–75 Recently, strong
scientific evidence shows that treatment of diabetic nephrop-
athy reduces cardiovascular complications as well as renal
failure. The UK Prospective Diabetes Study,73,74 the Steno-2
Study,75 and the ADVANCE trial76 all demonstrate that tight
control of blood glucose level and blood pressure (and lipids
in Steno-2) significantly reduces the incidence and progres-
sion of diabetic kidney disease. In people with type 2
diabetes, inhibition of the renin–angiotensin–aldosterone
system using an angiotensin-converting enzyme inhibitor or
an angiotensin receptor blocker decreased progression from
normoalbuminuria to microalbuminuria,77 reduced progres-
sion from microalbuminuria to macroalbuminuria,78 and
slowed the development of ESRD.79 Even in underprivileged
minorities, simple measures of intervention reduce the
burden of ESRD, as documented by evidence-based inter-
vention programs in communities of Australian aborigi-
nals.80,81 Thus the use of an angiotensin-converting enzyme
inhibitor targeted at proteinuria and independent of blood
pressure is now standard therapy for patients with diabetic
nephropathy in addition to glucose, lipid, and blood pressure
control.6
There are several examples of demonstration projects that
have implemented early detection and prevention in develo-
ping countries. In India, young women were trained to
measure blood pressure and carry out simple urine tests, and
the cheapest drugs, reserpine and hydrochlorothiazide,
metformin, and glibenclamide, were administered.82–85 Blood
pressures lower than 140/90 mm Hg were achieved in 96% of
people with hypertension, and a hemoglobin A1c level lower
than 7% was achieved in 52% of people with diabetes82 at an
annual per capita cost of $0.27.82 These encouraging findings
indicate that simple and inexpensive strategies of early
intervention are feasible and effective even in low-income
settings.
CKD and cardiovascular disease
Hypertension. Raised blood pressure is a key NCD risk
factor, and its prevalence, like those of diabetes and
cardiovascular disease, is projected to increase sharply over
the next few decades—especially in developing nations.86
Nearly 1 billion people worldwide have high blood pressure
(defined as 4140/90 mm Hg). That number is higher if the
currently recommended blood pressure goal of 130/80 is
used, and it is expected to rise to 1.56 billion people by 2025,
increasing by 24% in developed countries and by 80% in
developing regions such as Africa and Latin America.86 The
prevalence of hypertension is highest in non-Hispanic blacks
(53%) versus whites (43%) or Mexican Americans (34%).
Moreover, hypertension, like diabetes and CKD, is more
common in overweight or obese people (60% for body mass
indexX35 versus 32% for body mass index of 23).87 As with
CKD, awareness of hypertension is low. Slightly more than
half of US adults with hypertension were aware of their
disease in 1999–2004; fewer than half were treated for their
hypertension with medications; and fewer than two-thirds of
those achieved good control.8,19 This problem is worse in
developing countries.88 For low- and middle-income coun-
tries, the WHO recommends an absolute risk approach for
cost-effectively lowering the cardiovascular risk of all people
with raised blood pressure to prevent heart attacks, strokes,
and renal disease.80 A combination of population-wide and
individual health-care interventions is required to make
control of hypertension affordable and equitable in these
lower income settings.1,6,89–91
i. CKD is a cause and consequence of hypertension. CKD is
both a cause and a consequence of hypertension. Kidney
dysfunction is a major cause of hypertension, and hyperten-
sion in turn aggravates CKD and accelerates its progression.85
The presence of CKD is a common and underappreciated
cause of resistant hypertension.92 Hypertension is now the
major risk factor for development and progression of diabetic
and nondiabetic CKD.86,93
ii. Hypertension often coexists with and exacerbates CKD.
The prevalence of hypertension is significantly higher
(50–60%) in people with CKD than in the general population
and rises to 90% in CKD patients aged more than 65 years.19
In the United States, approximately 26% of people with
hypertension have concomitant CKD.16,19 In CKD screening
studies in the general population, the presence of micro-
albuminuria has been shown to predict later development of
hypertension.94 The renal consequences of hypertension are
uniquely exaggerated in the CKD population because a loss
of the normal nocturnal decline in blood pressure (‘dipping’)
usually occurs, which aggravates the severity of daytime
elevations and is more closely associated with proteinuria
than with GFR.95 Other observations also suggest co-primacy
of hypertension and CKD in the etiology of cardiovascular
disease,96 emphasizing the interrelated nature of these
conditions.
iii. Control of hypertension is especially suboptimal when
CKD is also present. Not only is the adverse renal and
cardiovascular impact of hypertension increased in the
setting of CKD, but the likelihood that hypertension will be
appropriately controlled is substantially reduced when it
coexists with CKD—especially when diabetes or proteinuria
is also present.86,87,97 In the US National Kidney Foundation’s
Kidney Early Evaluation Program (KEEP; a health-screening
program for people at high risk for CKD), the prevalence
(86%), awareness (80%), and treatment (70%) of hyperten-
sion in the screened cohort were high, but good blood
control was achieved in only 13%.97 NHANES data compiled
by the US Centers for Disease Control and Prevention
Chronic Kidney Disease Surveillance Team also document
significantly poorer blood pressure control in patients with
CKD.98
iv. Opportunistic screening for CKD in people with hyper-
tension may help to improve outcomes. Many studies
document the beneficial effect of blood pressure control on
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renal as well as cardiovascular outcomes in both adults
and children.99–101 There is no direct evidence that screening
for CKD will further improve outcomes in hypertensive
patients as compared with simply measuring and treating
blood pressure alone. However, indirect evidence suggests
that screening for CKD in this population is beneficial. First,
the treatment of hypertension may require modification or
intensification in the setting of concomitant CKD,86,98
suggesting that knowledge of a patient’s CKD status would
be clinically useful. For example, evidence-based manage-
ment of hypertension in CKD should include inhibition
of the renin–angiotensin system, and perhaps lower systolic
blood pressure targets—especially if proteinuria is also
present.102,103 Second, data from the KEEP screening
program demonstrate that blood pressure control is better
among patients who are aware that they have CKD, as
compared with those who are unaware97—perhaps because
this knowledge motivates patients to adhere to appropriate
care. This observation is supported by data from Bolivia
indicating that physicians are more likely to manage
hypertension appropriately once CKD is identified.104
Cardiovascular disease (excluding hypertension). i. Cardio-
vascular disease is a major public-health problem. Cardio-
vascular disease is the most common NCD—accounting for
about 30% of all deaths worldwide and 10% of all healthy life
lost to disease.1,4 Well-established conventional risk factors
for premature cardiovascular disease include tobacco use,
physical inactivity, unhealthy diet, obesity, diabetes, hyper-
tension, and hyperlipidemia as well as age and male
gender.1,105,106 Although mortality from cardiovascular dis-
ease has been declining in the general population in
developed countries, no such decline is seen in developing
countries, minority populations, or people with accompany-
ing CKD.19,31 Cardiovascular disease itself is a major risk
factor for CKD107,108 and is associated with substantial
increases in the incidence of CKD (acute myocardial
infarction, 33%; congestive heart failure, 46%).107,108
ii. CKD is a major independent risk factor for cardiovascular
disease. It has long been appreciated that there is a 20- to
30-fold increase in cardiovascular disease in patients with
ESRD. In 2004, it was definitely shown that even milder
forms of CKD are associated with excess cardiovascular risk:
a community-based study of over 1 million US adults noted
an independent and graded association between GFR and
risk of death, cardiovascular events, and hospitalizations.9
Increased risk in patients with CKD has been demonstrated
for angina, myocardial infarction, heart failure, stroke,
peripheral vascular disease, arrhythmias, and sudden
death.30,31,109
iii. Even mild reductions in GFR are associated with
substantial increases in cardiovascular risk. More evidence
that this increased cardiovascular risk is attributable to CKD
and not solely to coexisting diabetes or hypertension has been
provided in subsequent studies. For example, in a study of
6447 people followed for a mean period of 7 years, the risk
of cardiac death was increased 46% in people with GFR
between 30 and 60 ml/min (stage 3 CKD) independent of
traditional cardiovascular risk factors including diabetes and
hypertension.110 The Cardiovascular Health Study of over
6000 US adults showed a risk for cardiovascular events and
mortality in people over 55 with CKD alone that was
equivalent to that in patients with diabetes or previous
myocardial infarction.111 In another study, the hazard ratio
for cardiac death was actually higher in patients with CKD
(relative risk 1.96) than in patients with diabetes (relative
risk 1.49) or demonstrable myocardial perfusion defects
(relative risk 1.90).112 The increased risk of cardiovascular
disease associated with CKD has been well documented in
both general19,112,113 and high-risk113 populations. The excess
risk is not confined to the elderly—in a study of 31,000
community volunteers with an average age of 45, the
presence of CKD doubled the risk for myocardial infarction,
stroke, and all-cause mortality.114 Nor is the excess risk
confined to white populations: CKD is an important risk
factor for mortality among US30 and African blacks,115 as
well as in people from Asia.116 Reviewing ten community-
based cohort studies in Japan and adjusting for diabetes and
hypertension as risk factors, Ninomiya et al. reported a
57% greater risk of cardiovascular disease in patients with
GFR less than 60 compared with those with GFR greater than
90 ml/min.117
iv. Albuminuria and proteinuria are also independently
associated with excess cardiovascular risk. The risk of mortality
is better correlated with proteinuria (albuminuria) than with
GFR alone.31,116,118,119 A large population-based study of
more than 1 million people from Alberta, Canada, demon-
strated that the presence of proteinuria was associated with
marked increases in the risk of all-cause mortality and the
risk of kidney failure, independent of GFR and at all levels of
baseline kidney function.29 Similar associations linking
proteinuria to stroke, myocardial infarction, and coronary
revascularization have also been reported.120,121 Data from
the US NHANES database confirm the increased risk of
cardiovascular disease both with reduced GFR and with
albuminuria and document the independent effect of
albuminuria on risk of both cardiovascular disease and all-
cause mortality at all levels of GFR; for example, the presence
of microalbuminuria almost doubles the cardiovascular
disease rate in patients with GFR of 16–59 (stage 3–4 CKD)
and 60–89 ml/min (stage 2 CKD).119 Although there has been
concern that CKD identified by reduced GFR alone is found
predominantly in older adults,122 the association between
proteinuria and cardiovascular mortality independent of
hypertension, diabetes, and GFR has recently been demon-
strated in a meta-analysis of 22 studies30 including partici-
pants with a wide range of ages from around the world. The
independent risk associated with proteinuria for all-cause
mortality, cardiovascular mortality, and progression to ESRD
was confirmed in over 1.1 million people with proteinuria
identified only by detection of ‘trace’ or greater on dipstick
urinalysis, as well as in over 100,000 who had an albumin/
creatinine ratio (ACR) of 10 mg/g or more.30 Similar findings
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were consistent in younger and older participants and are
supported by a meta-analysis of ten cohorts of 266,975
people at increased risk of CKD that demonstrated increased
risk for both cardiovascular disease and all-cause mortality
with both reduced GFR and increased albuminuria indepen-
dently of each other.123
These findings have also been confirmed in a broad range
of ethnic populations. For example, in a study of 96,736
Japanese adults 40–79 years old followed for 10 years, Irie
et al. confirmed the independent and additive effects of both
proteinuria and reduced GFR on the risk of cardiovascular
death.124 The prognostic importance of proteinuria is also
observed in people with cardiovascular disease. For example,
in survivors of myocardial infarction, proteinuria was
associated with a higher risk of death than reduced GFR.125
Similar findings were reported in patients with congestive
heart failure but without diabetes, hypertension, or reduced
GFR, in whom increased albuminuria was strongly associated
with both cardiovascular and all-cause mortality.126 Another
study indicates that not only did the likelihood of
cardiovascular events increase, but the time to development
of a cardiovascular event is significantly and independently
reduced in the presence of proteinuria at all levels of GFR.127
Most of these studies have quantified proteinuria using
laboratory-determined albumin/creatinine or protein/creati-
nine ratios. However, semiquantitative, point-of-care mea-
sures of proteinuria that do not require a laboratory are also
effective for risk stratification at all levels of baseline
GFR.29,120,128,129 In a large community-based study of
1,120,295 adults, Go et al. showed that the presence of 1þ
or greater proteinuria identified by dipstick urine testing
increased the risk of developing cardiovascular disease by
30%, independent of baseline GFR.9
A recent paper examined the contribution of eGFR and
ACR independent of traditional risk factors to the prediction
of risk for cardiovascular and renal outcomes, using a sample
of people with established cardiovascular disease who
participated in two clinical trials.130 The data again showed
that GFR and ACR were important independent predictors of
progressive renal function loss. Although the authors also
found that the renal parameters added little for prediction of
cardiovascular risk, their analysis used a very restrictive
definition of risk classification based on arbitrary risk
categories and focused on people who already had cardio-
vascular disease. Since this study included a limited number
of people with heavy proteinuria, its conclusions may not be
generalizable to the broader population with CKD. For
example, recent data from the Uppsala Longitudinal Study of
Adult Men study in 1113 older men indicate that both GFR
and albuminuria did improve cardiovascular disease risk
prediction beyond traditional cardiovascular risk factors in
the population that did not have prevalent cardiovascular
disease.131
The excess risk associated with albuminuria extends
to very low levels that were considered innocuous until
recently (15–29 mg/d). A population-based study from
the Netherlands demonstrated an exponential relationship
between albuminuria and the risk of cardiovascular death—
with a nearly 50% increase in risk observed for albuminuria
of 15–29 mg/d, as compared with albuminuria less than
15 mg/d. In contrast, the risk was increased sixfold among
people with albuminuria exceeding 300 mg/d.118 The Third
Copenhagen Heart Study confirmed an increased risk of
coronary disease and mortality at very low levels of albumin
excretion independent of other risk factors including
hypertension and diabetes.132 Such levels of albuminuria
are also independently associated with increases in left
ventricular mass, an established predictor of subsequent
cardiovascular events.133 Moreover, subdividing stage 3 CKD
according to the presence or absence of a urinary albumin
excretion rate greater than 30 mg/d improves cardiovascular
risk stratification, further indicating the predictor value of
albuminuria.134
Further emphasizing the independent nature of albumin-
uria as an independent risk factor, a positive association
between albuminuria and all-cause mortality was found in
nondiabetic, nonhypertensive people after a 4.4-year follow-
up.135 An ACR greater than 6.7 mg/mg in three urine samples
increased the risk for all-cause mortality 2.4-fold. Subjects
with an ACR greater than or equal to the sex-specific median
(43.9 mg/g for men, 47.5 mg/g for women) experienced a
nearly threefold increased risk of cardiovascular disease
(adjusted hazard ratio 2.92, Po0.001) and a borderline-
significantly increased risk of death (adjusted hazard ratio
1.75, P¼ 0.08) compared with those with an ACR below the
median.136 Among people without hypertension or diabetes,
baseline presence of albuminuria predicted development
of blood pressure incrementally over established risk factors
and at levels well below the conventional threshold for
microalbuminuria.137
Thus, multiple studies confirm that proteinuria (a
parameter that has been included by the WHO as an
essential diagnostic test for primary care6) is in fact a graded
risk factor for cardiovascular disease independent of GFR,
hypertension, diabetes, and traditional cardiovascular risk
factors and that this risk extends down into ranges of
albumin excretion generally considered normal.118,134,138–143
v. Identification and treatment of CKD may also reduce
cardiovascular risk. Interventions designed specifically to
reduce proteinuria and slow progression of CKD also
effectively reduce cardiovascular risk. The benefits of therapy
with an angiotensin-converting enzyme inhibitor (ACEI) for
slowing progression of established diabetic and nondiabetic
CKD are well established.99,100,144,145 Recent data indicate
that, independent of other risk factors (including baseline
GFR), more rapid loss of kidney function is strongly
associated with the risk of coronary events, suggesting that
interventions that prevent kidney function loss may also
prevent cardiovascular events.146 Another analysis in people
with type 2 diabetes showed that the risk of cardiovascular
outcomes was significantly reduced in proportion to the
reduction of albuminuria with ACEI therapy; every 50%
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reduction in albuminuria was associated with an 18%
reduction in cardiovascular risk, and albuminuria was
the only predictor of cardiovascular outcome.147 Other
studies also show that changes in proteinuria are more
predictive of outcomes than the change in blood pressure
achieved with ACEI therapy.148 These findings suggest that
treatments targeting proteinuria specifically (such as higher
doses of renin–angiotensin system blockers than are required for
blood pressure control) may further improve clinical outcomes,
independent of their effects on blood pressure or GFR.149
A pilot randomized controlled trial that identified people
from the general population who had albuminuria and
randomized them to receive an ACEI versus placebo found a
trend toward reduction in cardiovascular events over 4 years
even in people with no other risk factors.147 In this study,
treatment was most effective (and likely to be cost-effective)
in people with albumin excretion greater than 50 mg/d.150
The Heart Outcomes Prevention Evaluation (HOPE) study
also reported a decrease in cardiovascular mortality in high-
risk people with CKD (reduced GFR) who were treated with
ACEIs;89 the relative benefit in this population was similar to
the benefit in people without CKD, but the absolute benefit
was greater in those with CKD because of the higher base-
line risk. Combination, multimodal therapy of people with
reduced GFR and/or albuminuria (using blood pressure
control, ACEIs/angiotensin receptor blockers, sodium
restriction, statins, and aspirin) was associated with highly
favorable cardiovascular outcomes and stability of kidney
function.151 These data indicate that treatment of CKD as
defined by either low GFR or albuminuria will improve
health by delaying or preventing cardiovascular disease.
Summary
CKD is an important public-health problem that is closely
linked to other major NCDs such as diabetes and
cardiovascular disease (including hypertension)—but which
independently increases the likelihood of adverse outcomes
and high health-care costs, suggesting that it can be used to
identify the highest risk subset of patients, who may benefit
most from treatment. Further, optimal management of these
other NCDs may require modification when CKD is also
present.
THE RATIONALE FOR EARLY DETECTION OF CKD THROUGH
A PRIMARY HEALTH CARE APPROACH
i. Measuring albuminuria and GFR in populations at risk for
NCDs would meaningfully enhance risk prediction. Laboratory
measurements of albuminuria and serum creatinine (to
estimate GFR) are potentially useful additions to assessment
of cardiovascular risk in primary-care settings. Measurement
of urine albumin is already recommended for cardiovascular
risk assessment in primary care even in resource-constrained
settings.6 Measurement of serum creatinine in selected
patient groups is also recommended but is not feasible
in primary-care settings at present in most low-income
countries. The importance of considering proteinuria and
reduced GFR separately is illustrated by the fact that in the
United States only 25% of people with proteinuria have
reduced GFR and only 25% of those with a low GFR have
proteinuria152—and thus, focusing on either alone would
miss a substantial proportion of people at risk. Albuminuria
has been shown to predict the development of both
hypertension94,137 and diabetic nephropathy.74 Finally, in-
creases in albumin excretion can precede elevations in both
blood sugar and blood pressure—thus identifying a popula-
tion of patients that would not be detected by conventional
screening methods for diabetes or hypertension.137
ii. Measuring albuminuria in populations at risk for NCDs
is practical and inexpensive. Readily available, inexpensive
measurements of proteinuria using dipstick urinalysis alone
are sufficient to identify high-risk patients.9,125,138 Albumin
dipsticks have a sensitivity of 88%, specificity of 80%,
positive predictive value of 89%, and negative predictive
value of 92% for detection of albuminuria—adequate for
screening in most point-of-care settings.138 More sophisti-
cated measurements such as albumin/creatinine or protein/
creatinine ratio are more sensitive for detection of less severe
proteinuria but are more expensive and can be less easy to
use at the point of care.153
CKD can be identified opportunistically during health-
care encounters for management of other NCDs. For
example, among nondiabetic subjects with normal serum
creatinine levels undergoing percutaneous coronary inter-
ventions, about 78% had demonstrable CKD when screened
more stringently for renal function (GFR, urine protein);
17% of those older than 65 years and 5% of those younger
than 65 years had stage 3 or worse CKD.154 The presence of
CKD likely accelerated the development of coronary disease
in these patients but also appears to increase their risk of
periprocedural hemorrhage, contrast nephropathy, restenosis,
and death.155 CKD can also be identified in economically
disadvantaged settings by mobile clinics and point-of-care
laboratory testing. For example, a recent study from Mexico
found that more than 30% of people with no history of
cardiovascular disease who agreed to be screened for CKD
and other cardiovascular risk factors had a projected risk
of 30% for a cardiovascular event in the next 5 years.127
A further 27% of these people had CKD that had not been
previously recognized.
A recent high-quality economic analysis showed that using
GFR to screen people from the general population with
diabetes for CKD was highly cost-effective, independent of
age.129 Previous studies have reached similar conclusions
about the benefits of screening using dipstick urinalysis or
protein/creatinine ratio in people with diabetes, as well as
the cost-effectiveness of treatments directed at reducing
proteinuria in the subset of this population who are found
to have CKD.156 No direct evidence currently demonstrates
the effectiveness and cost-effectiveness of screening for
CKD in nondiabetic people without additional CKD risk
factors.157 However, because identification of CKD is
expected to change management and improve outcomes
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(see below), screening for CKD in nondiabetic patients older
than 55 years is currently recommended.33,158
iii. Identification of CKD would change management of
NCDs and improve outcomes. The rationale for including the
prevention (or the slowing of the progression) of kidney
disease in the public-health agenda for NCDs is usually
provided by promises to reduce the enormous cost of renal
replacement therapy. However, the substantial impact of
CKD on cardiovascular disease and increases in costs
associated with CKD itself provide a much more compelling
rationale for including screening for CKD in government
health programs, especially in high-risk populations. One
example is the need to alter management of patients with
CKD to minimize the increased risk of AKI mentioned above.
iv. Early detection of CKD in developed countries. A recent
expert panel has made recommendations to the US Centers
for Disease Control and Prevention on how to accomplish
this.159 The implementation of mandatory calculation of
GFR whenever serum creatinine is measured in countries
such as the United States and the United Kingdom, accom-
panied by information to providers on how to interpret these
values, has led to significant increases in both awareness and
detection of CKD. A number of entities now collect and
report data on CKD in the population, including surveillance
systems such as the US Renal Data System,160 the National
Health and Nutrition Examination Survey (NHANES),161 the
regional ESRD Networks,162 and the Quality Improvement
Organization system.159 Similar renal registries now exist in
most developed countries. In the United States, the National
Kidney Foundation’s Kidney Early Evaluation Program
(KEEP) carries out systematic screening and kidney disease
education in high-risk groups.163 Several awareness programs
are sponsored by the National Institutes of Health through
the National Kidney Disease Education Program.164 The US
Centers for Disease Control and Prevention through their
Chronic Kidney Disease Initiative are undertaking CKD
surveillance programs and an economic impact study
designed to meet national Healthy People 2010 objectives
and have developed new diagnostic codes for CKD.165 The
United Kingdom has recommended increased attention to
early screening for CKD and added CKD screening as part
of primary-care doctors’ chronic-disease assessment incen-
tive payments. In 2000, the National Kidney Foundation of
Singapore initiated a comprehensive program that has
screened more than 450,000 people and has already reduced
the risk of progressive CKD and related NCDs among
Singaporeans.166 Effective programs aimed at preventing,
identifying, and treating CKD have led to substantial
reductions in the incidence of ESRD in Japan and promising
improvements in the prevalence of CKD in Australia and
Taiwan.17,167
v. Health systems of developing countries are already scaling
up efforts to identify and treat CKD. In the developing world
the challenges are considerably greater.1,2,7 However, signi-
ficant progress is being made. The Kidney Disease: Improving
Global Outcomes (KDIGO) group continues to develop
evidence-based approaches to providing care to kidney
patients.168,169 The International Society of Nephrology
(ISN), through its Global Outreach Research and Prevention
Committee, has focused on demonstrating that early detec-
tion and prevention programs can be carried out cost-
effectively in very resource-poor settings using the Chronic
Kidney Disease, Hypertension, Diabetes and Cardiovascular
Disease (KHDC) template.170,171 KHDC projects have now
been supported and implemented at a research level in 22
settings in 15 countries, and data from over 60,000 screened
people undergoing longitudinal follow-up are being collected
and analyzed at the Kidney Disease Data Center at the Mario
Negri Research Institute in Bergamo, Italy.172 This ISN
program has also assumed responsibility for collecting and
analyzing data on renal and urologic diseases for the WHO
Global Burden of Diseases, Injuries, and Risk Factors Study
(the GBD 2005 Study), which is now ongoing.171 A recent
survey by the International Federation of Kidney Foundations
evaluated CKD screening programs in 28 countries (most in
the developing world) and showed significant improvement in
program performance between 2005 and 2007, with con-
tinued growth expected.173 National health systems in some
developing countries, such as Uruguay, have already incorpo-
rated CKD into their NCD prevention and control programs.
Mexico has recently launched the Strategic Network of Health
Services against Chronic Kidney Disease. However, before
such efforts are expanded on a national scale, it is necessary to
obtain more information on sustainability, opportunity costs,
and affordability of such programs to the public sector of low-
and middle-income countries.
vi. Efforts to raise awareness about CKD. Important as all
of these surveillance and data-gathering programs are, the
resources to implement effective early detection and preven-
tion programs for CKD (like all NCDs) must ultimately
come from government health programs to improve the
public health, to decrease the costs of managing CKD and
cardiovascular disease, and to respond to public demand.
World Kidney Day is a joint initiative of ISN and the
International Federation of Kidney Foundations, which is
organized to raise awareness regarding CKD. The sixth World
Kidney Day (2011) focused on the kidney and cardiovascular
disease and was celebrated with events in over 100 countries
that included public activities such as free screenings for
CKD and also meetings between leaders in the renal
community and high-level government officials (including
health ministers, prime ministers, and even presidents).63
Over the next few years, continued growth of World Kidney
Day is expected, allowing its associated activities to be
progressively more effective for increasing awareness of CKD
(and the other NCDs that often accompany CKD, such as
diabetes, hypertension, and cardiovascular disease) among
the general public as well as government decision makers.
SUMMARY AND ACTION PLAN FOR THE FUTURE
Top priority for prevention of all NCDs (including CKD)
must focus on effective and cost-effective methods to control
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tobacco use, reduce harmful use of alcohol, facilitate
physical activity, and promote a healthy diet (including
salt reduction in processed food). In addition, individual
disease-specific health-care interventions are also required to
address those with disease or at high risk of developing
disease. Ironically, some government programs that reim-
burse the enormous cost of renal replacement therapy often
provide little or no incentive to conduct inexpensive early
detection and prevention programs that have the potential to
reduce those costs in the future. There is strong evidence
supporting the detection and treatment of CKD as a key
component of integrated national NCD strategies.39 The
major benefits will occur in people at high risk and in
developing countries. Simple and inexpensive measurements
of proteinuria (and, if affordable, GFR) can be used for case
finding, especially in high-risk populations, including people
over 55 and those with diabetes, hypertension, cardiovascular
disease, and a family history of kidney disease. These
recommendations are already incorporated in the WHO
package of essential NCD interventions for primary care and
have been incorporated into government policies in several
developed countries, including the United States, the United
Kingdom, Japan, Australia, and Canada. Further efforts to
implement the inexpensive, cost-effective interventions now
available to treat people found to have CKD (including
reduction in proteinuria, and control of traditional
cardiovascular risk factors) must be extended to other
countries—especially in the developing world, where the
burden of NCDs is especially high. Such interventions will
reduce the risk of both ESRD and cardiovascular disease—
and thereby improve health outcomes to the maximum
extent possible.
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